Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Discordance between Physiology and Imaging Guided PCI in Intermediate Coronary Lesions: Who to trust?

As regards intermediate coronary lesion intervention, physiological assessment is essential for culprit lesion identification and clinical decision making. It has been shown, in a randomized study, that physiology-guided percutaneous coronary intervention (PCI), along with intravascular ultrasound (IVUS), is not inferior for the combined two-year outcome of all-cause death, acute myocardial infarction (AMI), and revascularization.

Currently, the combination of these strategies is considered best practice. However, their discrepancies and clinical implications remain unclear.

The aim of this post-hoc analysis of the FLAVOUR study (Fractional Flow Reserve and Intravascular Ultrasound for Clinical Outcomes in Patients with Intermediate Stenosis) was to evaluate the discrepancy and relevance of physiological assessment in IVUS-guided PCI.

The Primary Endpoint was major adverse cardiovascular events (MACE) incidence, defined as a composite of death, acute myocardial infarction (AMI), and revascularization, at one-year follow-up.

Read also: Edge-to-Edge Repair in Atrial Secondary Tricuspid Regurgitation.

The Secondary Endpoint included angina frequency and quality of life, a per the Seattle Angina Questionnaire. Patients were classified based on IVUS use for PCI guidance (performed vs. deferred PCI) and QFR value, as follows:

Deferred Group: Negative QFR + deferred PCI.

Performed Group: Negative QFR + performed PCI.

Reference Group: Positive QFR + performed PCI.

34.4% of the 784 analyzed patients belonged to the deferred group, 29.3% to the performed group, and 31.5% to the reference group. Mean age was approximately 65, and most participants were male. The most frequently treated coronary artery was the left anterior descending, followed by the right coronary.

Cumulative MACE incidence at two years was 4.5%, 3.9%, and 9.4% for the deferred, performed, and reference groups, respectively (P = 0.019). MACE risk resulted higher among reference group patients vs. the performed group (HR: 2.46; 95% CI: 1.13–5.35; P = 0.023) and the deferred group (HR: 2.17; 95% CI: 1.07–4.38; P = 0.031). 

Read also: Trends in the Treatment of Critical Lower Limb Ischemia.

In patients with negative QFR, there were no prognostic differences between the performed and deferred groups as regards MACE (HR: 0.88; 95% CI: 0.37–2.11; P = 0.779) or AMI (HR: 1.48; 95% CI: 0.49–4.45; P = 0.484), and neither were there differences in secondary end point.

Conclusión 

Angiography-based physiological assessment may provide additional prognostic information in patients undergoing IVUS-guided PCI. IVUS guided PCI may not be beneficial in patients with functionally non-significant lesions. This sub-analysis should serve as springboard to generate new hypotheses and continue to evaluate the combination of these two therapeutic tools.

Original Title: Clinical Relevance of Discordance Between Physiology-and Imaging Guided PCI Strategies in Intermediate Coronary Stenosis.

Reference: Jinlong Zhang,MD,PHD et al JACC Cardiovasc Interv 2024. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Andrés Rodríguez
Dr. Andrés Rodríguez
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...